Stock 688298 ZHEJIANG ORIENT GENE BIOTECH CO.,LTD
Add to a list
To use this feature you must be a member
Log inSign up

All News Zhejiang Orient Gene Biotech Co.,Ltd

Equities

688298

CNE100003RM8

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-06-12 pm EDT 		5-day change 1st Jan Change
28.11 CNY -0.32% Intraday chart for Zhejiang Orient Gene Biotech Co.,Ltd -3.07% -21.39%
Jun. 12 US FDA Grants Emergency Use Authorization to Orient Gene Biotech's COVID-19 Test Kit MT
May. 16 Orient Gene Biotech's US Unit Gets FDA Clearance for Fentanyl Detectors MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
US FDA Grants Emergency Use Authorization to Orient Gene Biotech's COVID-19 Test Kit
MT
Orient Gene Biotech's US Unit Gets FDA Clearance for Fentanyl Detectors
MT
Zhejiang Orient Gene Biotech Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Zhejiang Orient Gene Biotech's Unit Gets US FDA's Nod to Register Two Products
MT
Zhejiang Orient Gene Biotech Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Zhejiang Orient Gene Biotech Co.,Ltd announces an Equity Buyback for CNY 100 million worth of its shares.
CI
Zhejiang Orient Gene Biotech Co.,Ltd authorizes a Buyback Plan.
CI
Zhejiang Orient Gene Obtains Veterinary GMP Certificate, Production License
MT
Zhejiang Orient Gene Biotech Co.,Ltd(SHSE:688298) dropped from Shanghai Stock Exchange Health Care Sector Index
CI
Zhejiang Orient Gene Biotech Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Zhejiang Orient Gene Biotech Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Orient Gene Biotech Registers New In Vitro Diagnostic Reagents
MT
Zhejiang Orient Gene Biotech Elects Chairman, Vice Chairman
MT
Zhejiang Orient Gene Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Zhejiang Orient Gene Registers Two Medical Devices in EU, US
MT
Zhejiang Orient Gene Biotech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
IN BRIEF: Omega Diagnostics receives CD4 deferred consideration
AN
Zhejiang Orient Gene Biotech Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
CI
Zhejiang Orient Gene Biotech Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
CI
Omega Diagnostics Up 16% With Sale Of Loss-Making CD4 Business
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 688298 Stock
  4. News Zhejiang Orient Gene Biotech Co.,Ltd